Core Insights - The Zacks Style Scores are designed to help investors select stocks with the highest potential to outperform the market over the next 30 days, utilizing ratings from A to F based on value, growth, and momentum characteristics [2][10]. Summary by Category Value Score - The Value Style Score identifies attractive and discounted stocks using various financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow, appealing to value investors seeking good stocks at favorable prices [3]. Growth Score - The Growth Style Score focuses on a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow to find stocks with sustainable growth potential [4]. Momentum Score - The Momentum Style Score assists momentum investors by evaluating trends in stock prices and earnings outlooks, using metrics like one-week price changes and monthly earnings estimate changes to identify optimal buying opportunities [5]. VGM Score - The VGM Score combines the Value, Growth, and Momentum Style Scores, serving as a comprehensive indicator to identify stocks with the best overall characteristics in terms of value, growth forecast, and momentum [6]. Zacks Rank - The Zacks Rank is a proprietary stock-rating model that leverages earnings estimate revisions to guide investors in building successful portfolios, with 1 (Strong Buy) stocks historically yielding an average annual return of +23.75% since 1988, significantly outperforming the S&P 500 [7][8]. Stock to Watch: TransMedics (TMDX) - TransMedics Group, a medical technology company, is currently rated 3 (Hold) on the Zacks Rank with a VGM Score of A. The company has a Momentum Style Score of A, with shares increasing by 11.3% over the past four weeks [12]. - For fiscal 2025, the Zacks Consensus Estimate for TransMedics has risen by $0.42 to $2.32 per share, with four analysts revising their earnings estimates upwards in the last 60 days. The company has an average earnings surprise of +45.4% [13].

Core Insights - Zacks Premium provides various tools to enhance stock market investment confidence and effectiveness [1][2] Zacks Style Scores - Zacks Style Scores are indicators that assist investors in selecting stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [3] - The Value Score identifies attractive and discounted stocks using ratios like P/E, PEG, and Price/Sales [4] - The Growth Score focuses on a company's financial strength and future outlook, analyzing projected and historical earnings, sales, and cash flow [5] - The Momentum Score helps investors capitalize on price or earnings trends, utilizing one-week price changes and monthly earnings estimate changes [6] - The VGM Score combines all three Style Scores, serving as a crucial indicator alongside the Zacks Rank for identifying stocks with strong value, growth, and momentum [7] Zacks Rank and Performance - The Zacks Rank is a proprietary stock-rating model that leverages earnings estimate revisions to aid in portfolio creation [8] - Stocks rated 1 (Strong Buy) have achieved an average annual return of +23.75% since 1988, significantly outperforming the S&P 500 [9] - There are over 800 top-rated stocks available, making it essential to utilize Style Scores for effective selection [10] Investment Strategy - To maximize returns, investors should target stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [11] - Stocks with lower ranks but high Style Scores may still pose risks if they have downward-trending earnings forecasts [12] Company Spotlight: TransMedics Group - TransMedics Group (TMDX) is a medical technology company focused on organ transplant therapy, currently rated 3 (Hold) with a VGM Score of A [13] - TMDX is projected to experience a year-over-year earnings growth of 129.7% for the current fiscal year, making it appealing for growth investors [13][14] - The Zacks Consensus Estimate for TMDX has risen by $0.42 to $2.32 per share, with an average earnings surprise of +45.4% [14]

Summary of TransMedics Group (TMDX) FY Conference August 12, 2025 Company Overview - **Company**: TransMedics Group (TMDX) - **Industry**: Organ transplantation technology Key Points and Arguments 1. **Vision and Impact**: TransMedics aims to increase the number of organ transplants and improve post-transplant outcomes. From 2022 to 2024, total adult transplants in the U.S. grew by 20%, but only 2% when excluding TransMedics, indicating a significant positive impact by the company [2][3][4]. 2. **Clinical Outcomes**: The OCS technology has demonstrated superior outcomes, with ischemic biliary complications at 2.1% for TransMedics compared to 11% for competitors, highlighting the effectiveness of their technology [5]. 3. **TransMedics Trident**: The company's growth strategy is based on three pillars: - OCS multi-organ platform for organ preservation - National OCS Program with 17 hubs across the U.S. - Vertically integrated logistics network, including a fleet of 21 jets for efficient organ transport [6][7][8]. 4. **Market Potential**: In the U.S., there are approximately 17,000 organ donors annually, with significant waste in organ utilization (e.g., 80% of lungs, 75% of hearts, and 40% of livers are wasted). This presents a substantial growth opportunity for TransMedics [11][12][13]. 5. **Growth Projections**: The company expects to reach over $1 billion in revenue by 2028 with 10,000 transplants, aiming for a 30% operating margin. The growth model is scalable and efficient, with expanding margins as the business grows [17][18]. 6. **International Expansion**: TransMedics sees significant growth potential not only in the U.S. but also in international markets, which are being targeted for expansion [18]. 7. **Clinical Trials**: The company is preparing to launch heart and lung trials, with expectations to enroll the first patients by the end of 2025. Revenue from these trials is not included in current guidance, indicating potential upside [24][26][51]. 8. **Market Share**: Current market shares are approximately 35% in liver, 26% in heart, and 4% in lung. The company aims to improve organ utilization and gain market share to achieve its growth targets [33][34]. 9. **Kidney Market Opportunity**: The kidney transplant market is competitive, with over 20,000 transplants annually. TransMedics plans to leverage its technology to improve outcomes and reduce the need for post-transplant dialysis [52][54]. Additional Important Content - **Logistics and Maintenance**: The logistics team is confident in managing the maintenance of their fleet, ensuring operational efficiency. The current mix of transportation is approximately 30-40% ground and the rest aviation [39][47]. - **Service Margin Guidance**: The overall gross margin for TransMedics is expected to be around 60%, with variations based on service and product margins [29]. This summary encapsulates the key insights and strategic directions discussed during the conference, highlighting TransMedics' commitment to enhancing organ transplantation outcomes and its growth potential in the market.

Core Viewpoint - TransMedics (TMDX) is showing potential for investment due to a recent breakout above the 50-day moving average, indicating a short-term bullish trend [1] Technical Analysis - TMDX has reached a key level of support and has moved higher by 8.9% over the past four weeks [2] - The 50-day simple moving average is considered significant for establishing support and resistance levels, making TMDX's recent performance noteworthy [2] Earnings Estimates - There have been no downward revisions in earnings estimates for TMDX in the past two months, with four upward revisions noted, indicating positive sentiment [3] - The consensus earnings estimate for TMDX has also increased, reinforcing the bullish outlook for the company [3]

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market engagement and confidence [1] - The Zacks Style Scores are designed to assist investors in selecting stocks with the highest potential to outperform the market in the short term [2] Zacks Style Scores Overview - Stocks are rated from A to F based on value, growth, and momentum characteristics, with A being the highest score indicating better chances of outperforming [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5][6] Value Score - Focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - Evaluates stocks based on projected and historical earnings, sales, and cash flow to identify sustainable growth opportunities [4] Momentum Score - Targets stocks experiencing upward or downward trends in price or earnings, utilizing factors like one-week price change and monthly earnings estimate changes [5] VGM Score - Combines all three Style Scores to provide a comprehensive indicator for investors who utilize multiple investing strategies [6] Zacks Rank Integration - The Zacks Rank leverages earnings estimate revisions to guide investors in building successful portfolios [7] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +23.75% since 1988, significantly outperforming the S&P 500 [8] Stock Selection Strategy - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [9] - Stocks with lower ranks (3, 4, or 5) should be approached cautiously, even if they have high Style Scores [10] Company Spotlight: TransMedics Group (TMDX) - TransMedics is a medical technology company focused on organ transplant therapy for end-stage organ failure patients [11] - Currently rated 3 (Hold) with a VGM Score of A and a Momentum Style Score of A, indicating potential for momentum investors [11] - Recent upward revisions in earnings estimates for fiscal 2025 have increased the Zacks Consensus Estimate by $0.42 to $2.32 per share, with an average earnings surprise of +45.4% [12]

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1][2][8] Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum, helping investors identify stocks likely to outperform the market in the next 30 days [2][3] - Each stock receives a rating from A to F, with A indicating the highest potential for outperformance [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] Value Score - The Value Style Score identifies stocks trading below their true value by analyzing ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - The Growth Style Score assesses a company's financial strength and future outlook, focusing on projected and historical earnings, sales, and cash flow [4] Momentum Score - The Momentum Style Score evaluates stocks based on price trends and earnings outlook, utilizing short-term price changes and monthly earnings estimate changes [5] VGM Score - The VGM Score combines the three Style Scores to identify stocks with attractive value, strong growth forecasts, and promising momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to help investors build successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +23.75% since 1988 [7][9] - There are over 800 stocks rated 1 or 2, making it essential for investors to use Style Scores to narrow down their choices [8] Stock Example: TransMedics Group (TMDX) - TransMedics Group, a medical technology company, is rated 3 (Hold) with a VGM Score of A and a Growth Style Score of A, indicating strong growth potential [11] - The company is forecasted to achieve year-over-year earnings growth of 106.9% for the current fiscal year [11] - Recent analyst revisions have increased the Zacks Consensus Estimate for fiscal 2025 by $0.20 to $2.09 per share, with an average earnings surprise of +45.4% [12]

Core Insights - TransMedics Group, Inc. has received conditional approval from the FDA for its Investigational Device Exemption (IDE) to initiate the Next-Generation OCS ENHANCE Heart trial, which aims to transform organ transplant therapy for patients with end-stage organ failure [1][3] Group 1: Trial Details - The ENHANCE trial consists of two parts: Part A focuses on prolonged heart perfusion using the OCS™ Heart System, while Part B aims to demonstrate the superiority of OCS Heart perfusion in donation after brain death (DBD) cases compared to static cold storage methods [2] - The total sample size for the ENHANCE trial is expected to exceed 650 patients, potentially making it the largest heart preservation trial for transplant globally [2] Group 2: Company Overview - TransMedics is a leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation, headquartered in Andover, Massachusetts [4] - The company was founded to address the unmet need for better organ transplantation solutions and has developed technologies to preserve organ quality and assess organ viability prior to transplant [4]

Core Insights - TransMedics Group, Inc. (TMDX) reported a significant increase in earnings per share (EPS) of 92 cents for Q2 2025, marking a 162.9% year-over-year growth and exceeding the Zacks Consensus Estimate by 91.7% [1][6] Revenue Performance - TMDX achieved revenues of $157.4 million in Q2 2025, reflecting a 37.7% increase year-over-year and surpassing the Zacks Consensus Estimate by 6.8% [2][6] - The revenue growth was attributed to higher utilization of the Organ Care System (OCS), particularly in liver and heart transplants, and additional income from TransMedics logistics services [2][6] - Net product revenues reached $96.1 million, up 33.9% year-over-year, driven by increased organ utilization [4][6] - Service revenues totaled $61.3 million, a 43.9% increase year-over-year, primarily due to logistics services [7][6] Margin and Profitability - Operating profit for the quarter was $36.6 million, representing a 192.3% increase from the previous year, with an operating margin expansion of 1230 basis points to 23.2% [9][6] - Gross profit increased by 39.4% year-over-year to $96.6 million, with a gross margin of 61% [8][6] Financial Position - At the end of Q2 2025, TransMedics had cash reserves of $400.6 million, up from $310.1 million at the end of Q1 2025, while total long-term debt remained relatively stable at $59.5 million [10] - Cumulative net cash provided by operations was $88.8 million, significantly higher than $22.3 million at the end of Q2 2024 [10] Future Outlook - The company has raised its revenue guidance for 2025, now expecting revenues between $585 million and $605 million, indicating a 35% growth at the midpoint compared to 2024 [11] - Management highlighted ongoing expansion plans, including the upcoming OCS Kidney launch and the growth of the NOP logistics network, positioning the company for future growth [14][13]

Richard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can be achieved by identifying businesses with secular growth opportunities in markets with barriers to entry. Narweena's research process is focused on company and industry fundamentals with the goal of uncovering unique insights. Narweena has a high risk appetite and a long-term ...

Core Insights - TransMedics Group reported strong Q2 2025 earnings, exceeding Wall Street expectations with GAAP revenue of $157.4 million and GAAP EPS of $0.92, reflecting a year-over-year revenue increase of 38% [1][2] - The company raised its full-year revenue guidance to $585 million to $605 million, indicating approximately 35% growth over the previous year [14] Financial Performance - Q2 2025 GAAP revenue was $157.4 million, surpassing the estimate of $147.7 million and up from $114.3 million in Q2 2024, marking a 37.7% year-over-year increase [2] - GAAP EPS reached $0.92, significantly higher than the estimated $0.45 and up 162.9% from $0.35 in Q2 2024 [2] - Net income soared to $34.9 million, a 186.1% increase from $12.2 million in the prior year, representing 22% of revenue [2][6] Business Operations - The company focuses on two main areas: expanding the adoption of its FDA-approved Organ Care System (OCS) and scaling the National OCS Program (NOP) for organ transport logistics [4][3] - The OCS technology allows for better preservation of donor organs, leading to more successful transplants, particularly in liver and heart transplants [3][9] Revenue Breakdown - Product revenue grew by 34% year-over-year, while service revenue surged by 44%, with service revenue accounting for $61.3 million [5] - Gross margin remained stable at 61%, despite an increase in lower-margin service revenue [6] Strategic Developments - The company is investing in R&D and logistics, with cash reserves at $400.6 million and plans to expand its aircraft fleet to 22 by year-end [7][8] - The launch of the NOP ACCESS digital platform aims to enhance operational efficiency and automate billing processes [10] Regulatory and Market Position - TransMedics received conditional Investigational Device Exemption (IDE) clearance for next-generation OCS Lung trials, expected to start in the second half of 2025 [11] - The company is also expanding its manufacturing infrastructure in Italy to support international growth and ensure supply continuity [12] Reimbursement Strategies - The company emphasizes reimbursement for both the OCS device and NOP logistics services through U.S. Medicare and commercial insurers, assisting transplant centers with billing [13] Future Outlook - Management anticipates at least 400 basis points of operating margin improvement in 2025, driven by efficiency gains and scaling effects [8][14] - Increased investment in R&D and upcoming clinical trials for next-generation OCS devices are expected to contribute to long-term growth [15]